185 related articles for article (PubMed ID: 35999268)
1. CHK2 activation contributes to the development of oxaliplatin resistance in colorectal cancer.
Hsieh CC; Hsu SH; Lin CY; Liaw HJ; Li TW; Jiang KY; Chiang NJ; Chen SH; Lin BW; Chen PC; Chan RH; Lin PC; Yeh YM; Shen CH
Br J Cancer; 2022 Nov; 127(9):1615-1628. PubMed ID: 35999268
[TBL] [Abstract][Full Text] [Related]
2. Targeting type Iγ phosphatidylinositol phosphate kinase overcomes oxaliplatin resistance in colorectal cancer.
Yu M; Wang H; Zhao W; Ge X; Huang W; Lin F; Tang W; Li A; Liu S; Li RK; Jiang SH; Xue J
Theranostics; 2022; 12(9):4386-4398. PubMed ID: 35673560
[No Abstract] [Full Text] [Related]
3. CHK2-mediated regulation of PARP1 in oxidative DNA damage response.
Hsu PC; Gopinath RK; Hsueh YA; Shieh SY
Oncogene; 2019 Feb; 38(8):1166-1182. PubMed ID: 30254210
[TBL] [Abstract][Full Text] [Related]
4. LncRNA-NEF suppressed oxaliplatin resistance and epithelial-mesenchymal transition in colorectal cancer through epigenetically inactivating MEK/ERK signaling.
Shi CJ; Xue ZH; Zeng WQ; Deng LQ; Pang FX; Zhang FW; Fu WM; Zhang JF
Cancer Gene Ther; 2023 Jun; 30(6):855-865. PubMed ID: 36782047
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of Ataxia-Telangiectasia Mutated and RAD3-Related (
Combès E; Andrade AF; Tosi D; Michaud HA; Coquel F; Garambois V; Desigaud D; Jarlier M; Coquelle A; Pasero P; Bonnefoy N; Moreaux J; Martineau P; Del Rio M; Beijersbergen RL; Vezzio-Vie N; Gongora C
Cancer Res; 2019 Jun; 79(11):2933-2946. PubMed ID: 30987998
[TBL] [Abstract][Full Text] [Related]
6. Casein Kinase 2α Augments Oxaliplatin Resistance in Colorectal Cancer Cells by Increasing ABCE1 Expression.
Yun CW; Lee JH; Lee SH
Anticancer Res; 2023 Jun; 43(6):2519-2525. PubMed ID: 37247928
[TBL] [Abstract][Full Text] [Related]
7. Oxaliplatin responses in colorectal cancer cells are modulated by CHK2 kinase inhibitors.
Pires IM; Ward TH; Dive C
Br J Pharmacol; 2010 Mar; 159(6):1326-38. PubMed ID: 20128802
[TBL] [Abstract][Full Text] [Related]
8. SUMO2/3 promotes the progression and oxaliplatin resistance of colorectal cancer through facilitating the SUMOylation at Ku80-K307.
Feng D; He J; Yuan M; Chen Q; Zeng X; Zhou Q; Wu J; Han B
Biofactors; 2023; 49(6):1158-1173. PubMed ID: 37338025
[TBL] [Abstract][Full Text] [Related]
9. circHIPK3 promotes oxaliplatin-resistance in colorectal cancer through autophagy by sponging miR-637.
Zhang Y; Li C; Liu X; Wang Y; Zhao R; Yang Y; Zheng X; Zhang Y; Zhang X
EBioMedicine; 2019 Oct; 48():277-288. PubMed ID: 31631038
[TBL] [Abstract][Full Text] [Related]
10. Exosome-transmitted miR-128-3p increase chemosensitivity of oxaliplatin-resistant colorectal cancer.
Liu T; Zhang X; Du L; Wang Y; Liu X; Tian H; Wang L; Li P; Zhao Y; Duan W; Xie Y; Sun Z; Wang C
Mol Cancer; 2019 Mar; 18(1):43. PubMed ID: 30890168
[TBL] [Abstract][Full Text] [Related]
11. WD repeat domain 62 (WDR62) promotes resistance of colorectal cancer to oxaliplatin through modulating mitogen-activated protein kinase (MAPK) signaling.
Cai J; Su L; Luo W
Bioengineered; 2022 Jun; 13(6):14450-14459. PubMed ID: 35758246
[TBL] [Abstract][Full Text] [Related]
12. NFYB-induced high expression of E2F1 contributes to oxaliplatin resistance in colorectal cancer via the enhancement of CHK1 signaling.
Fang Z; Gong C; Yu S; Zhou W; Hassan W; Li H; Wang X; Hu Y; Gu K; Chen X; Hong B; Bao Y; Chen X; Zhang X; Liu H
Cancer Lett; 2018 Feb; 415():58-72. PubMed ID: 29203250
[TBL] [Abstract][Full Text] [Related]
13. WBSCR22 confers oxaliplatin resistance in human colorectal cancer.
Yan D; Tu L; Yuan H; Fang J; Cheng L; Zheng X; Wang X
Sci Rep; 2017 Nov; 7(1):15443. PubMed ID: 29133897
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of miR-19a partially reversed the resistance of colorectal cancer to oxaliplatin via PTEN/PI3K/AKT pathway.
Zhang Y; Liu X; Zhang J; Xu Y; Shao J; Hu Y; Shu P; Cheng H
Aging (Albany NY); 2020 Mar; 12(7):5640-5650. PubMed ID: 32209726
[TBL] [Abstract][Full Text] [Related]
15. Colorectal cancer organoid models uncover oxaliplatin-resistant mechanisms at single cell resolution.
Chen G; Gong T; Wang Z; Wang Z; Lin X; Chen S; Sun C; Zhao W; Kong Y; Ai H; Yang H; Liu Y; Wu F; Kang J; Zhao S; Xiao X; Sun J; He A; Li Z
Cell Oncol (Dordr); 2022 Dec; 45(6):1155-1167. PubMed ID: 36136268
[TBL] [Abstract][Full Text] [Related]
16. Tumor-Associated Macrophages Promote Oxaliplatin Resistance
Lan H; Liu Y; Liu J; Wang X; Guan Z; Du J; Jin K
Mol Pharm; 2021 Mar; 18(3):1026-1037. PubMed ID: 33555197
[TBL] [Abstract][Full Text] [Related]
17. KLF5 inhibition overcomes oxaliplatin resistance in patient-derived colorectal cancer organoids by restoring apoptotic response.
Shen X; Zhang Y; Xu Z; Gao H; Feng W; Li W; Miao Y; Xu Z; Zong Y; Zhao J; Lu A
Cell Death Dis; 2022 Apr; 13(4):303. PubMed ID: 35379798
[TBL] [Abstract][Full Text] [Related]
18. KIF18b-dependent hypomethylation of PARPBP gene promoter enhances oxaliplatin resistance in colorectal cancer.
Hong B; Lu R; Lou W; Bao Y; Qiao L; Hu Y; Liu K; Chen J; Bao D; Ye M; Fang Z; Gong C; Zhang X
Exp Cell Res; 2021 Oct; 407(2):112827. PubMed ID: 34508743
[TBL] [Abstract][Full Text] [Related]
19. Suppression MGP inhibits tumor proliferation and reverses oxaliplatin resistance in colorectal cancer.
Huang C; Wang M; Wang J; Wu D; Gao Y; Huang K; Yao X
Biochem Pharmacol; 2021 Jul; 189():114390. PubMed ID: 33359068
[TBL] [Abstract][Full Text] [Related]
20. Annexin A3 depletion overcomes resistance to oxaliplatin in colorectal cancer via the MAPK signaling pathway.
Xu R; Yin J; Zhang Y; Zhang S
J Cell Biochem; 2019 Sep; 120(9):14585-14593. PubMed ID: 30998268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
